Drug Trial Radar · NCT05364021
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 3, 2022
Primary completion
Nov 16, 2023
Study completion Nov 20, 2023
Sponsor
- Lead sponsor
- Longboard PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
Conditions
- Developmental and Epileptic Encephalopathy
- Dravet Syndrome
- Lennox Gastaut Syndrome
Interventions
LP352Drug
LP352 administered three times daily, orally or through G-tube
PlaceboDrug
Matching placebo for LP352 administered three times daily, orally or through G-tube
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse EventsTime frame: Baseline up to Day 75
- Columbia-Suicide Severity Rating Scale (C-SSRS) ResponseTime frame: Baseline up to Day 75
- Patient Health Questionnaire-9 Total Score and Question 9 ScoreTime frame: Baseline up to Day 75
- Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Treatment PeriodTime frame: Baseline up to Day 75
- Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Maintenance PeriodTime frame: Baseline up to Day 75
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona - Health Sciences Center
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Rancho Los Amigos National Rehabilitation Center (RLANRC)
Downey, California
Children's Hospital of Orange County
Orange, California
University of California San Francisco
San Francisco, California
Northwest Florida Clinical Research Group
Gulf Breeze, Florida
University of Miami
Miami, Florida
Advent Health Orlando
Orlando, Florida
Research Institute of Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology
Boise, Idaho
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Spectrum Health
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Boston Children's Health Physicians LLP
Hawthorne, New York
New York University Langone Hospital - Long Island
Mineola, New York
Northwell Health
New York, New York
Northeast Regional Epilepsy Group
Staten Island, New York
OnSite Clinical Solutions LLC
Charlotte, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Providence Neurological Specialties-East
Portland, Oregon
Child Neurology Consultants of Austin
Austin, Texas
Austin Epilepsy Care Center
Austin, Texas
University of Utah
Salt Lake City, Utah
University of Washington Valley Medical Center
Renton, Washington
Royal Brisbane Women's Hospital
Herston, Queensland, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Monash Children's Hospital, Monash Health
Clayton, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.